Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

The incidence was similar between the left and right breasts, with most patients diagnosed with grade 2 invasive ductal carcinoma, no vascular emboli, a human epidermal growth factor receptor 2 score ...

Abbreviations: CDK, cyclin-dependent kinase; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; TNBC, triple-negative breast cancer ... metastatic invasive lobular carcinoma.

Metastatic breast cancer market is projected to grow significantly through 2035, driven by rising cases, treatment advances, and expanding R&D investments.

In this phase II prospective study that included 101 evaluable patients, 36 of whom had residual disease at surgery, the negative predictive value ... Eligible patients included those with operable ...

Sometimes breast cancer can emerge between routine mammograms. Five years after recovery, one patient's story reinforces the ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...